We herein report on a mitochondrial therapeutic effect based on the delivery of coenzyme Q10 (CoQ10), an anti-oxidant, to in vivo mitochondria using a MITO-Porter, a liposome-based mitochondrial delivery system that functions via membrane fusion. To evaluate the effects, we used a mouse liver ischemia/reperfusion injury (I/R injury) model, in which mitochondrial reactive oxygen species are overexpressed. We packaged CoQ10 in the lipid phase of a MITO-Porter and optimized the mitochondrial fusogenic activities to produce the CoQ10-MITO-Porter. A histological observation of the carriers in the liver by confocal laser scanning microscopy was done and the accumulation of the carrier labeled with a radio isotope in the liver confirmed that the CoQ10-MITO-Porter was delivered to liver mitochondria via systemic injection. These analytical results permitted us to optimize the compositions of the CoQ10-MITO-Porter so as to permit it to efficiently accumulate in mouse liver mitochondria.
Introduction
In recent years, various mitochondrial dysfunctions have been implicated in a variety of diseases [1] [2] [3] . Thus, research and development directed toward mitochondrial medicine would be expected to have great medical benefits to society in general. Thus, researchers dealing with mitochondrial drug delivery systems are encouraged to develop such therapeutic strategies based on the in vivo mitochondrial delivery of therapeutics. Various types of mitochondrial delivery systems have been reported during the past decades [4] [5] [6] [7] [8] , but only a limited number of these approaches have the potential for use in mitochondrial therapy. These strategies face many problems including cell internalization, size limitations and the physicochemical properties of the cargo, modification of a functional device and the denaturation of the cargo [5, 9, 10] .
We previously reported on the construction of a MITO-Porter, a liposome-based mitochondrial delivery system that functions via membrane fusion [5, 11] . This membrane fusion mechanism-based strategy can deliver a cargo to mitochondria independent of its size and physical properties. To date, we have shown that the MITO-Porter can be used to deliver a variety of therapeutic cargoes, including an anti-apoptosis chemical and an anti-oxidant chemical, to the mitochondria of human cells [12, 13] . As a result, the mitochondrial delivery of therapeutic cargoes have potential for functioning as a mitochondrial therapeutic strategy, indicating that the MITO-Porter represents a potentially useful carrier for use in mitochondrial medicine, based on in vitro experiments.
The purpose of this study was to validate the utility of the mitochondrial therapeutic strategy by targeting in vivo mitochondria as shown in Figure 1 Reactive oxygen species (ROS) are mainly produced in the mitochondrial respiratory chain, and are associated with a variety of diseases including I/R injury, neurodegenerative diseases, tumor metastasis, metabolic syndrome and aging [5, [14] [15] [16] [17] [18] . Thus, a therapeutic strategy for the mitochondrial delivery of antioxidant chemicals could be useful for the treatment of these diseases. To evaluate the anti-oxidant effects resulting from the mitochondrial delivery of CoQ10, we used hepatic I/R injury induced mice that overexpress mitochondrial ROS in the liver. In such a situation, serum alanine aminotransferase (ALT) levels would be increased.
In this study, we prepared the CoQ10-MITO-Porter by the ethanol dilution method, in which CoQ10 is contained in the lipid envelopes of the MITO-Porter, and attempted appropriately adjust the size of the particles. We also investigated the effect of the size of the CoQ10-MITO-Porter on the distribution of the carrier in liver tissue post systemic injection by histological observations using confocal laser scanning microscopy (CLSM). A knowledge of the extent of mitochondrial binding and the fusogenic activities of the CoQ10-MITO-Porter permitted us to determine the optimal composition for the constructing a CoQ10-MITO-Porter with a high mitochondrial fusogenic activity. Histological observations by CLSM and the use of a carrier labeled with a radio isotope (RI) verified that the CoQ10-MITO-Porter was delivered liver mitochondria via systemic injection. Finally, we injected mice with the optimized CoQ10-MITO-Porter via the tail vein, and hepatic I/R injury was then induced, followed by measurements of serum ALT levels, a marker of liver injury. [19] was obtained from Kurabo Industries Ltd (Osaka, Japan). CoQ10 was obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 3 [20] , and the chemical structure is shown in Figure S2A . Mitochondria were isolated from mouse liver essentially, as described in Supplementary material. All other chemicals used were commercially available reagent-grade products.
Materials and methods

Experimental animals
C57BL/6 male mice (6 weeks old) were purchased from Japan SLC (Shizuoka, Japan). All animal protocols were approved by the institutional animal care and research advisory committee at the Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan (date: 22 March 2013, registration no. 13-0062).
Preparation of MITO-Porter and PEG-LP by lipid hydration method.
The lipid film for the MITO-Porter was produced on the bottom of a glass tube by the evaporation of a chloroform/ethanol solution containing 137.5 nmol lipids (DOPE/SM = 9:2, molar ratio). After the formation of the film, 250 μL of 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 7.4) was added, followed by incubation for 15 min at room temperature and sonication for 1 min in a bath-type sonicator (85W, Aiwa, Co., Tokyo, Japan). To attach R8 to the surface of the carrier, a solution of STR-R8 (10 mol% of total lipids) was added to the resulting suspensions, followed by incubation for 30 min at room temperature. In preparation of PEG-LP, the lipid film composed of DOPE/SM/DMG-PEG2000 (9/2/0.33, molar ratio) was used. The lipid compositions of these carriers are summarized in Table S1 . For histological observation shown in Figure 2A , the carriers were labeled with DiI (0.5 mol% of total lipids). For investigation of liver accumulation shown in Figure 2C , the carriers were labeled with [ 3 H]-CHE (0.023 mol% of total lipids).
Construction of carriers by the ethanol dilution method.
To evaluate the hepatoprotective effect from I/R injury (Figures 5, 6) , carriers containing CoQ10 were constructed by the ethanol dilution method by the following 4 steps as shown in Figure 3A . A 100% (v/v) EtOH solution containing 5.5 mM lipids [DOPE(or EPC)/SM/DMG-PEG2000 (9/2/0.33, molar ratio)] with/without CoQ10 (18 mol% of lipids) were prepared. The lipid in the EtOH solution was mixed with phosphate buffered saline (PBS (-)) under strong agitation to a concentration of 90% (v/v) EtOH (or 50% (v/v) EtOH for large sized CoQ10-MITO-Porter) (1) . The resulting suspension was then added to the PBS (-) under strong agitation to a final concentration of ~5% (v/v) EtOH (2) . The ethanol was removed by ultrafiltration through an Amicon system (MWCO 100,000; Millipore, Billerica, MA, USA), and the external buffer replaced with PBS (-) (3). To attach R8 to the surface of the carrier, a solution of STR-R8 (3 or 10 mol% lipids) was added to the resulting suspensions, followed by incubation for 30 min at room temperature (4) . The lipid compositions of these carriers are shown in Tables 1-3 and Table S2 . Figure 2C , the carriers labeled with [ 3 H]-CHE (0.019 mol% of total lipids) were prepared with HEPES buffer.
Characterization of carriers.
Particle diameters were measured using a dynamic light scattering method (Zetasizer Nano ZS;
Malvern Instruments, Worcestershire, UK). The values of particle diameters are shown in the form of volume distribution. The ζ-potentials of samples were also determined in 10 mM HEPES buffer using a Zetasizer Nano ZS. Encapsulation efficiency of the CoQ10 into MITO-Porter was estimated, as described in the Supplementary material.
Mitochondrial binding activity using isolated mitochondria.
The mitochondrial binding activity of the carrier was determined by fluorescence measurements.
A 270 μL aliquot of suspension of isolated mouse liver mitochondria (1 mg protein/mL) and a 30 μL aliquot of NBD labeled liposome (lipid concentration 0.55 mM) were mixed and incubated for 30 min at 
Membrane fusion assay using FRET analysis
The fusion activity of the carriers with isolated mitochondrial membranes was assessed by FRET as previously described [9, 11, 21] . In this experiment, lipid envelopes of the dual-labeled carriers were labeled with both NBD (excitation at 460 nm and emission at 534 nm) and rhodamine (excitation at 550 nm and emission at 590 nm) so that the energy would be transferred from NBD to rhodamine. where F, F0 and Fmax represent the fluorescence intensity of labeled carrier after incubation with mitochondria, the fluorescence intensity of labeled carrier after incubation without mitochondria, and the maximum fluorescence intensity after the Triton X-100 treatment, respectively.
Histological observation for distribution of the carrier in liver tissue.
For the histological observation of carriers in the liver, carriers labeled with DiI were intravenously administered to mice via the tail vein at a dose of 2.75-7.0 μmol/kg of lipids in a total volume of 10 mL/kg. At 1-hr after the administration, each animal was perfused with saline containing heparin (40 U/mL) to remove blood from the liver, which was then collected and washed once with saline and once with Hank's balanced salt solution. The liver was sectioned into 1 mm thick sections, and incubated for 30 min in HEPES buffer containing Hoechst 33342 (final concentration, 40 μg/mL) to stain the nuclei, GS-IB4-FITC (final concentration, 40 μg/mL) to stain blood vessels, followed by obtaining fluorescent images by CLSM (Nikon A1; Nikon Co. Ltd., Tokyo, Japan). The tissue specimens were excited with a 405 nm wavelength light from a Diode laser, 488 nm wavelength light from an Ar laser and 561 nm wavelength light from a DPSS laser. A series of images were obtained using a Nikon A1 confocal imaging system equipped with a water immersion objective lens (Plan Apo 60_1.20 PFS WI) and a 1st dichroic mirror (405/488/561/640). The three fluorescence detection channels (Ch) were set to the following filters: Ch1: 450/50 (blue color) for nuclei stained by Hoechst 33342, Ch2: 525/50 (green color) for blood vessels stained by GS-IB4-FITC, Ch3: 595/50 (red color) for carriers labeled with DiI.
Quantification of carrier accumulation in liver mitochondria by RI.
To quantify the amounts of carrier that had accumulated in liver mitochondria, carriers labeled with [ 3 H]-CHE were intravenously administered to mice via the tail vein at a dose of 2.75 μmol/kg lipids in a total volume of 10 mL/kg. At 1-hr after the administration, each animal was perfused with saline containing heparin (40 U/mL) to remove blood from the liver, which was then collected and washed with saline. All subsequent steps were carried out on ice. After removing them from the saline, the livers were placed in 3 mL of ice-cold MIB, and were then minced with scissors and ice-cold MIB was added to give a total volume of 9 mL. The suspension was homogenized in a glass homogenizer (30 mL capacity) with a pestle using 3 complete up and down cycles (~ 550 rpm). A portion of the resulting homogenate was denoted as the liver homogenate sample. The remaining homogenate was mixed with approximately 1 mL of MIB and centrifuged at 800g for 5 min. The supernatant was transferred to icecold tubes and centrifuged at 7,500g for 10 min. The pellets were washed twice with EDTA-free MIB and reprecipitated by centrifugation (16,000g, 10 min). The resulting pellets were resuspended with EDTA-free MIB and the resulting suspensions were used as the mitochondria-enriched fraction. The purity of mitochondria-enriched fraction was confirmed by Western blotting to detect organelle specific proteins: Cytochrome c oxidase subunit IV (COX IV), mitochondrial specific protein; Histone H3, nuclear specific protein; Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), cytosolic specific protein (see supplementary material for details). The protein concentrations of the liver homogenate and mitochondrial proteins were determined using a BCA protein assay kit (Pierce, Rockford, IL). The liver homogenate sample and the mitochondria-enriched fraction were lysed in Soluene-350 (Perkin Elmer) at 50°C over night, and 10 mL of Hionic Fluor (PerkinElmer) was added to lysate. RI counts of these samples were measured using an LSC-6100 (ALOKA, Tokyo, Japan). Liver accumulation and mitochondrial targeting activity were calculated as follows:
Liver accumulation (%) = RI counts of liver homogenate sample (dpm) / RI counts of injected total carriers labeled with [ 3 H]-CHE x100
Mitochondrial targeting activity (/mg mitochondria) = RI counts of mitochondria-enriched fraction (dpm/mg mitochondria) / RI counts of injected total carriers labeled with [ 3 H]-CHE
Evaluation of hepatoprotective effect from I/R injury after systemic injection of CoQ10-MITO-
Porter.
To evaluate anti-oxidant effects, we used hepatic I/R injury induced mice that overexpress mitochondrial ROS in the liver. In this experiment, it was assumed that the ROS damaged hepatocytes and the intracellular ALT would leak out of the cell, resulting in an increase in serum ALT levels.
Samples containing CoQ10 were administered to mice at a dose of 2.0 mg/kg CoQ10 in a total volume of 10 mL/kg. Mice were treated with naked CoQ10 and MitoQ in 100% (v/v) EtOH via an intraperitoneal injection and with other samples in PBS (-) via an intravenous injection. At 18-hr after the injection of the samples, hepatic I/R injury was induced, according to a previous report [22] . General anesthesia was induced by inhalation of the anesthetic, isoflurane. After laparotomy, all vessels (hepatic artery, portal vein, and bile duct) to the left and median liver lobes were clamped. After 60 min of ischemia, these vessels were unclamped and the circulation was restored for the specified reperfusion time period before killing the animal. At 3-hr after the reperfusion of the liver, blood was collected, followed by incubation at centrifugation at room temperature for 1 hr. To obtain serum, blood samples were centrifuged at 800g at 4°C for 5 min. Serum ALT-and aspartate aminotransferase (AST)-levels were then determined using a commercially available kit (Wako Pure Chemical Industries, Ltd. Osaka, Japan).
Statistical Analysis
Data are expressed as the mean ± S.D. for the indicated number of experiments. Statistical significances between two groups were examined by the unpaired student's t-test ( Figure 2C and Figure   6B ). For multiple comparisons, one way ANOVA was performed (Figures 4A, 4B, Figure 5 and Figure   6C ). Levels of P < 0.05 were considered to be significant.
Results
Distribution of the MITO-Porter in liver tissue and mitochondrial accumulation
We first investigated the distribution of the MITO-Porter in the liver after systemic injection of the carriers. We prepared the MITO-Porter with highly mitochondrial fusogenic envelopes [5, 9, 11, 21] , where, of the total lipids, 10 mol% R8 was modified on the carrier surface, by the hydration method. We also prepared PEG-LP without R8 as a control carrier. The physiochemical properties of these carriers are summarized in Table S1 . For histological observations, carriers labeled with DiI (red color) were Figure 2A ).
We then quantified the accumulation of the carrier in liver mitochondria after systemic injection.
To verify the mitochondrial delivery in the liver, the purity of the isolated mitochondria must be verified.
In this experiment, the livers were harvested following systemic injection and homogenized, and the mitochondria-enriched fraction was then isolated from the homogenate by differential centrifugation, as described in a previous report [11, 23] . Samples of the homogenate and mitochondria-enriched fraction were subjected to Western blotting using primary antibodies against COX IV, Histone H3 and GAPDH, as mitochondrial, nuclear and cytosolic fraction markers ( Figure 2B ). The data showed that only a band corresponding to COX IV was detected in the mitochondria-enriched fraction (lane 2 in Figure 2B ), indicating that the mitochondria were exclusively isolated from the liver.
In this experiment, we prepared a MITO-Porter and PEG-LP with similar lipid compositions described above, as shown in Table S1 , and the carriers labeled with [ 3 H]-CHE were then administered to mice via tail vein injection (2.75 μmol lipids/kg). At 1-hr after the administration, each animal was sacrificed, and the values of liver accumulation ((a) in Figure 2C ) and mitochondrial targeting activity Figure 2C ) were estimated from the [ 3 H] content in the liver and mitochondrial lysate. As shown in Figure 2C (a), the MITO-Porter accumulated in the liver much more efficiently than PEG-LP.
This result is in agreement with the histological observations shown in Figure 2A . Moreover, we confirmed that the use of the MITO-Porter resulted in a significant increase in mitochondrial targeting activity compared with that for PEG-LP ((b) in Figure 2C) ). These results indicate that the MITO-Porter that was validated for mitochondrial delivery in cultured cells was also able to reach the liver via systemic injection, followed by mitochondrial targeting in the liver.
Construction of CoQ10-MITO-Porter and visualization of the carriers in liver tissue
To reach hepatocytes after systemic administration of the CoQ10-MITO-Porter, the carrier is required to pass through small pores in endothelial cells (fenestra) as shown in Figure 1 . It is known that the size of the fenestra of mice are around 140 nm [24] , thus controlling the size of carrier would play an important role in the delivery of the carrier to hepatocytes. In this experiment, we prepared CoQ10-MITO-Porters with different diameters, and investigated the effect of carrier size on liver accumulation. Figure 3B ). On the other hand, only very weak signals in the liver were observed in the case of the large sized CoQ10-MITO-Porter ((c) in Figure 3B ), indicating that an optimal size of the CoQ10-MITO-Porter is needed to pass through fenestra to reach hepatocytes. Thus, we concluded that the size control of the CoQ10-MITO-Porter is an important factor in the accumulation of the carriers in the livers via systemic injection. Table 2 . The particle diameters were less than 100 nm and the ζ-potentials increased with increasing ratios of R8-modification. As shown in Figure 4A , the mitochondrial binding activity was increased, when the R8 modification was increased in the CoQ10-MITO-Porter. It was also that confirmed that the membrane fusion of CoQ10-MITO-Porter modified with 3 mol% of R8 had the highest activity, among the particles tested ( Figure 4B ).
We then obtained fluorescent images of the liver tissues after the systemic injection of the CoQ10-MITO-Porter modified with 3 mol% of R8 labeled with DiI (red) using CLSM, to verify whether the carriers were delivered to liver mitochondria the same as the CoQ10-MITO-Porter modified with 10 mol% of R8, as shown in Figure 3B . The physicochemical properties of the carriers were analyzed, and the results were confirmed that a positively charged particle with a diameter of around 90 nm was prepared ( Table 2 ). The encapsulation efficiency of CoQ10 into the MITO-Porter was high (86.3±3%, n=3). As shown in Figure 4C , the fluorescent labeled carriers had effectively accumulated in the liver, as evidenced by the red signals.
We also quantified the carrier accumulation in liver mitochondria after systemic injection by a similar procedure using RI labeled carriers as described above. As shown in Figure S1 , the CoQ10-MITO-Porter modified with 3 mol% of R8 accumulated in the liver and the mitochondria efficiently as well as the MITO-Porter without CoQ10. Moreover, we investigated the stability of CoQ10-MITO-Porter in serum via in vitro experiments, where the carriers were incubated with/without serum at 37 o C, followed by measuring the diameters of the particles. The findings indicated that the diameters of the carriers were comparable in presence/absence of serum ( Figure S3 ), suggesting that the CoQ10-MITO-Porter did not undergo aggregation in the serum within the 1 hr time period needed for it to accumulate in the liver. These results indicate that the CoQ10-MITO-Porter that was optimized for mitochondria fusogenic activity are able to reach the liver mitochondria via systemic injection. We used a CoQ10-MITO-Porter modified with 3 mol% R8 as the CoQ10-MITO-Porter in the following experiment.
Evaluation of protection from hepatic I/R injury by mitochondrial delivery of CoQ10 using MITO-Porter
To evaluate anti-oxidant effects, we used hepatic I/R injury model mice that overexpress mitochondrial ROS, where serum ALT levels would be expected to be increased. We confirmed that the magnitude of the serum ALT-levels of the hepatic I/R injury model mice were thousands of the value as shown in Figure 5 , while the value for normal mice was only several dozen (29±15 IU/L, n=3). This result is in general agreement with results from a previous report stating that serum ALT-levels of hepatic I/R injury model mice to normal mice showed an extremely high value [15, 22] , indicating that the I/R injury is actually caused in the liver of our model mouse. Table 3 . We also used MitoQ as a positive control of a mitochondrial targeting antioxidant. As shown in Figure 5 , the CoQ10-MITO-Porter resulted in a significant decrease in serum ALT levels compared with 
Discussion
We confirmed the utility of a mitochondrial therapeutic strategy that involves targeting in vivo mitochondria using a MITO-Porter, which delivered therapeutic cargoes to mitochondria and showed a mitochondrial therapeutic effect as well as in an in vitro experiment [12, 13] . In the present study, the MITO-Porter was designed to deliver therapeutic cargoes to liver mitochondria of mice via systemic injection for prevention of hepatic I/R injury. Thus, we first investigated the distribution of the MITO-Porter in the liver after systemic injection of the carriers. Fortunately, the systemic injection of a MITO-Porter, in which the carrier surface was modified with R8, proved to be effective for targeting liver tissue, as shown in Figures 2A and 2C(a) . We previously reported that intravenously injected R8modified carriers effectively accumulated in the liver, resulting in a high transgene expression [25] .
Previous biodistribution studies showed that the R8-modified carriers rapidly accumulated in the liver within 10 min and that the accumulation in other tissues including kidney, lung and spleen were significantly lower compared to the liver [26, 27] . We confirmed the same tendency that the liver accumulation of the CoQ10-MITO-Porter (10 mol% of R8) was higher than in other tissues ( Figure S4 ).
Although the mechanism responsible for the liver accumulation of R8-modified carriers is unknown, it is possible that R8 might function as a specific ligand for hepatocytes and that carriers with a cationic charge could be recognized by macrophages of the liver. In future studies, we plan to investigate the distribution of MITO-Porter between hepatocytes and hepatic macrophages in mice livers after the systemic injection.
Moreover, we confirmed that the MITO-Porter localized in mitochondria in the liver, as shown in Figure 2C(b) . A previous investigation using isolated rat liver mitochondria showed that the modification of the carrier-surface with R8 significantly enhanced binding to mitochondria [5] . A similar result was observed in the case of mitochondria isolated from the livers of mice (data not shown).
Thus, we concluded that the R8 contained in the MITO-Porter was an important factor in the successful accumulation of the carriers in the liver, when administered by systemic injection and that mitochondrial targeting had been achieved.
We also investigated the effect of the size of the carrier on the liver accumulation via the systemic injection, because the carrier is required to pass through fenestra to reach the hepatocyte as shown in Figure 1 . It is known that fenestra are small pores in the vascular endothelial cells of the sinusoid, and the size of fenestra vary with species [24] . As shown in Figure 3B (b) , we observed that numerous carriers had accumulated in the liver cells after systemic injection of a small sized CoQ10-MITO-Porter with a diameter less than 100 nm. It is presumed that the small sized carriers would be able to easily pass through the fenestra of mice with a diameter around 140 nm [24] , while the large sized carriers with a diameter more than 300 nm would pass only with difficulty ( Figure 3B (c) ). On the other hand, the MITO-Porter with a diameter of around 200 nm would be slightly larger than the fenestra size of mice and probably would be able to pass the fenestra (Figure 2A(b) and 2C(a) ), because the fenestra size for a mouse is around 140 nm and has wide size distribution. In the case of humans, the fenestra size is around 100 nm and the size distribution is quite narrow [28] . Thus, the size control of the carrier would play a more important role, in carriers accumulating in the human liver when administered via systemic injection.
While, the MITO-Porter could be recognized by the reticuloendothelial system, which includes Kupffer cells of the liver and the splenic macrophages. In such a case, the MITO-Porter that accumulated in the liver would be distributed in both hepatocytes and Kupffer cells. On the other hand, biodistribution studies ( Figure S4 ) indicated that the MITO-Porter effectively accumulated in the liver escaping from splenic macrophages. This result is agreement with findings of a previous report in which R8-modified carriers with diameters less than 200 nm accumulated in the liver more efficiently than in the spleen [26, 27] . The cause of this phenomenon may be explained by the previous reports showing that the liposome size affects the biodistribution after the systemic injection of the carriers [29, 30] . In that study, liposomes containing ganglioside GM1 with a diameter in excess of 300 nm were trapped by splenic macrophages and disappeared in the blood circulation, while the optimal size range of liposomes for a high blood concentration were from 70 to 200 nm [30] . Collectively, it was presumed that the MITO-Porter (diameter = around 200 nm) and the small sized CoQ10-MITO-Porter (diameter < 100 nm) avoided uptake by the spleen, and the carriers modified with R8 then accumulated in the liver. Since CoQ10 has a benzoquinone ring linked to 10 isoprene units, is a well-known antioxidant which has properties that are potentially beneficial for preventing cellular damage during an I/R injury [31, 32] .
However CoQ10 has highly hydrophobic characteristics and a negative charge, which limits its accessibility in naked form to the intracellular mitochondria, which possess a highly negative charge. To date, a number of studies focusing on pharmaceutical formulations of CoQ10 have been reported in attempts to improve the low bioavailability of the largely insoluble CoQ10 [32, 33] . In the present study, we designed a CoQ10-MITO-Porter, in which CoQ10 was contained in a mitochondria-fusogenic lipid composition and attempted to deliver it to mitochondria. In a previous study, we described the preparation of a MITO-Porter by the hydration method, a relatively easy and simple method [11] . We first attempted to prepare a CoQ10-MITO-Porter using the same procedure, which includes the formation of a lipid film for the MITO-Porter with CoQ10 on the bottom of a glass tube, hydration of the lipid film with a buffer and sonication to produce vesicles. However, the methods were not optimal in this case, because it was not possible to remove the CoQ10 from the glass tube. Therefore, we investigated the preparation of a CoQ10-MITO-Porter by the ethanol dilution method and reverse phase evaporation method, which do not involve the process of the lipid formation. Both preparation methods permitted the construction of a CoQ10-MITO-Porter. In this experiment, we adopted the ethanol dilution method, because, using this method, it is relatively easy to control the size of the CoQ10 containing carriers by just varying a concentration of EtOH in the presence of PEG-lipids.
A FRET analysis using isolated mouse mitochondria showed that the mitochondrial membrane fusion of CoQ10-MITO-Porter modified with 3 mol% of R8 was significantly higher than that prepared with 10 mol% of R8 ( Figure 4B ). While, a conventional MITO-Porter without CoQ10 and PEG (DOPE/SM/STR-R8 = 9/2/1, molar ratio) showed a high membrane fusion activity with mouse liver mitochondria (76±11%, n=3). Thus, we concluded that the CoQ10 and PEG contained in CoQ10-MITO-Porter affected the mitochondrial membrane fusion property of the carrier. On the other hand, the mitochondrial binding activity was increased, when the R8 modification was increased in the CoQ10-MITO-Porter ( Figure 4A ). As shown in Table 2 , the ζ-potentials of the CoQ10-MITO-Porter were increased with increasing R8-modification. This suggests that R8 modification results in a positive charge on the carrier surface, which largely contributes to mitochondrial binding with the carriers via electrostatic interactions.
To evaluate the anti-oxidant effects of the CoQ10-MITO-Porter, we used MitoQ ( Figure S2A ) as a positive control for a mitochondrial targeting antioxidant. To date, the utilities of a therapeutic strategy using MitoQ have been demonstrated in in vivo experiments using various disease model animals [15, [34] [35] [36] . Moreover, MitoQ has been investigated in clinical trials [20, 37, 38] and is expected to be promising candidate for a mitochondrial medicine. MitoQ was also investigated for protection of the liver and heart from I/R injury in in vivo experiments using I/R injury induced mice and rats [15, 39, 40] .
We synthesized MitoQ essentially as described in a previous report [20] , and confirmed that the MitoQ was actually produced as evidenced by MS analyses for the MitoQ (calculated MW583 and observed Figure S2B ), using 100% EtOH as a vehicle. A dose of 5.0 mg/kg CoQ10 resulted in a therapeutic effect, while the administration of 2.5 mg/kg of CoQ10 was comparable with vehicle in serum ALT levels. In a previous report [15] , the administration of 1.0 mg/kg CoQ10 to mice via intraperitoneal injection showed a therapeutic effect. The difference in the applied dose for a therapeutic effect with the present study can be attributed to differences in the experiment conditions used.
As shown in Figure 5 , the systemic injection of the CoQ10-MITO-Porter achieved protection from a hepatic I/R injury. We conclude that this therapeutic effect resulted from the delivery of CoQ10 to mice liver mitochondria by the MITO-Porter via membrane fusion. To validate this issue, we investigated the mitochondrial binding and fusion activities of carriers on protection from hepatic I/R injury. In this experiment, we prepared a CoQ10-EPC-LP with low binding and fusion activities and
CoQ10-R8-EPC-LP with high binding and low fusion activities. For the mitochondrial binding assay and Figure 6A . The values for CoQ10-MITO-Porter (3 mol% of R8), data shown in Figure 4 were used. MITO-Porter and EPC-LP were used as vehicles (see the Table 3 for the detail).
Relative ALT value (a) and AST value (b) were evaluated after the hepatic I/R injury (B, C). Data are represented as the mean ± S.D. (n = 4-6). In Figure 6B , significant differences were determined by unpaired Student' s t-test (*p < 0.05). In Figure 6C , significant differences between vehicle and others were calculated by one-way ANOVA, and no significant difference (N.S.) was found.
mitochondrial fusogenic activity assay, fluorescent labeled carriers were prepared and the physicochemical properties of the carriers are summarized in Table S2 , and the mitochondrial binding and fusion activities are shown in Figure 6A . For the values for the CoQ10-MITO-Porter (3 mol% of R8), the data shown in Figures 4A and 4B were used.
We then administered samples containing CoQ10 to mice via intravenous injection, and induced hepatic I/R injury, followed by measuring the serum ALT and AST levels. The physicochemical properties used in this evaluation are summarized in Table 3 . As shown in Figure 6 
Conclusion
We report on the successful delivery of CoQ10 to liver mitochondria of mice via the systemic injection of a CoQ10-MITO-Porter. We confirmed that controlling the size of the carrier is an important factor and that the use of R8 contributed to liver accumulation and the mitochondrial targeting. We also confirmed that the in vivo mitochondrial delivery of CoQ10 Data are means ± S.D. (n=3-5). Figure   6A . For the values of CoQ10-MITO-Porter (3 mol% of R8), data shown in Figure 4 were used. MITO-Porter and EPC-LP were used as vehicles (see the Table 3 for the detail). Relative ALT value (a) and
Figure legends
AST value (b) were evaluated after the hepatic I/R injury (B, C). Data are represented as the mean ± S.D.
(n = 4-6). In Figure 6B , significant differences were determined by unpaired Student' s t-test (*p < 0.05).
In Figure 6C , significant differences between vehicle and others were calculated by one-way ANOVA, and no significant difference (N.S.) was found.
SUPPLEMENTARY MATERIAL
Supplementary Methods
Isolation of mitochondria from mouse livers
Mitochondria were isolated from livers obtained from C57BL/6 male mice (6 weeks of age).
Mice were sacrificed, and the livers were removed after the bleeding was performed with a heparin solution (40 U/mL), which was then collected and washed with saline. All subsequent steps were carried out on ice. After removing the saline, the livers were placed in 3 mL of ice-cold mitochondrial isolation buffer [MIB: 250mM sucrose, 2 mM Tris-HCl, 1 mM EDTA, pH 7.4], and were then minced with scissors and ice-cold MIB (+) was added to a total volume of 9 mL. The suspension homogenized in a glass homogenizer (30 mL capacity) with a pestle using 3 complete up and down cycles (~ 550 rpm).
The homogenate was mixed with approximately 1 mL of MIB (+) and centrifuged at 800g for 5 min.
The supernatant was transferred into ice-cold tubes and centrifuged at 7,500g for 10 min. The pellets were washed twice with EDTA-free MIB and reprecipitated by centrifugation (16,000g, 10 min), and the pellets were resuspended with EDTA-free MIB and the resulting suspensions were used as the isolated mitochondrial suspension. Protein concentrations of mitochondrial proteins were determined using a BCA protein assay kit (Pierce, Rockford, IL).
Estimation of encapsulation efficiency of the CoQ10 into MITO-Porter.
To estimate encapsulation efficiency, a CoQ10-MITO-Porter (DOPE/SM/STR-R8/DMG-PEG2000/CoQ10 [9/2/0.33/0.33/1.8]) containing a lipid film labeled with DiI (0.5 mol% of total lipids) was prepared using the ethanol dilution method as described in Materials and methods of the main text. Supplementary Table   Table S1 . Characteristics of the carriers prepared by hydration methods.
Carriers labeled with 0.5 mol% DiI were used for histological observation of the carriers in the liver. 
